Traditional cell engineering methods often permanently alter cells. In this #HowCellsWork episode, learn how transient approaches can create powerful therapeutics without permanently changing the cell – potentially broadening disease applicability and reducing long-term safety risks!
Jun 6, 2022
In this #HowCellsWork episode, learn how AACs can act as messengers, delivering instructions to the immune system on how to identify and attack cancer cells!
Therapeutic engineering with mRNA offers many exciting cell reprogramming possibilities. In this #HCW episode, we show how immune cells engineered with mRNA can provide Killer T cells with specific instructions and other capabilities to support an attack on tumors!
Feb 5, 2022
TIL therapies have shown potential for impact across multiple solid tumors. One challenge, however, is the use of IL-2 administration to support TIL function. Our latest #HowCellsWork story illustrates this challenge and potential solutions that could improve patient outcomes.
In this story, we explore some of the fundamental differences between autologous and allogeneic cell therapy manufacturing. The two main cell-sourcing strategies for cell therapy have different trade-offs. Autologous cells reduce the chances of a negative immunological reaction, while allogeneic cells can be more cost-effective.
Sep 29, 2021